Synlogic presents data at digestive disease week (ddw) on a novel approach for the treatment of inflammatory bowel disease

Cambridge, mass., may 23, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop synthetic biotic™ medicines for the treatment of  inflammatory bowel disease (ibd) during digestive disease week (ddw), being held virtually may 21-23, 2021.
SYBX Ratings Summary
SYBX Quant Ranking